ERα is overexpressed in thyroid cancers and oestrogen antagonists have been proposed as a treatment [78]; therefore, LMTK3, as a modulator of ERα, may represent a useful target in thyroid carcinomas. Here, ESR1 is linked to thyroid gland carcinoma.